A ProSpective, multicentre, registry to evalUate the Clinical outCome of Encruso RAL-EverolimusEluting Coronary Stent System in real world percutaneOus coronary revasculaRization in Indian population- SUCCESSOR - SUCCESSOR

ano Therapeutics Private Limited0 个研究点目标入组 0 人开始时间: 待定最近更新: 2024年5月27日

试验速览

暂无简介。

•1.Male or female patient who is 18 years and above
•2.Patients undergoing percutaneous coronary intervention with Encruso RAL-Everolimus Eluting Coronary Stent System
•3.Patient or legal guardian understands the study requirements and provides written informed consent
•4.Patient who is on dual antiplatelet therapy for at least 6 months post procedure

•1.Patient has known hypersensitivity or allergies to Aspirin, Heparin,Clopidogrel, Ticlopidine, Everolimus or similar drugs, or any other
•analogue or derivative, cobalt, chromium, or contrast media
•2.Patient with life expectancy less than 2 years
•3.Pregnant and lactating females or planning to become pregnant while in the study
•4.Patient currently participating in another investigational drug or device clinical trial

发起方

ano Therapeutics Private Limited